A carregar...
HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise
The US Food and Drug Administration (FDA) approved oral daily tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis of human immunodeficiency virus (HIV) infection in 2012 on the basis of two randomized controlled trials (RCTs), one in men who have sex with men (MSM) and another in HIV sero...
Na minha lista:
| Publicado no: | Clin Pharmacol Ther |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6925668/ https://ncbi.nlm.nih.gov/pubmed/30199098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1227 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|